|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Molecular Genetics |
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada M5G-1X5 (H.D., L.R., X.W., N.L., A.N., A.G.); and Division of Neurosurgery, Division of Neuropathology, Department of Pathology and Laboratory Medicine, The Toronto Hospital and University of Toronto, Ontario, Canada M5T-2S8 (P.S., A.G.)
2 Address correspondence and reprint requests to Abhijit Guha, FRCSC, 2-415 McLaughlin Pav., Western Div., UHN, 399 Bathurst St., Toronto, Ontario, Canada M5T-2S8.
Abstract
Vascular endothelial growth factor (VEGF) is a major inducer of tumor angiogenesis and edema in human astrocytomas by its interaction with cognate endothelial-specific receptors (VEGFR1/R2). Tie1 and Tie2/Tek are more recently identified endothelial-specific receptors, with angiopoietins being ligands for the latter. These angiogenic factors and receptors are crucial for the maturation of the vascular system, but their role in tumor angiogenesis, particularly in astrocytomas, is unknown. In this study, we demonstrate that the angiopoietin family member Ang1 is expressed by some of the astrocytoma cell lines. In contrast to VEGF, Ang1 is down regulated by hypoxia. Ang2 was not overexpressed. Expression profiles of low-grade astrocytoma specimens were similar to those of normal brain, with low levels of Ang1, Ang2, and VEGF expression. Glioblastoma multiforme expressed higher levels of Ang1, but not to the same degree as pseudopalisading astrocytoma cells around necrotic and hypoxic zones expressed VEGF, as shown in previous studies. Ang2 expression in the highly proliferative tumor vascular endothelium was also increased, as was phosphorylated Tie2/Tek. The expression profile of these angiogenic factors and their endothelial cell receptors in human glioblastomas multiforme was similar to that in a transgenic mouse model of glioblastoma multiforme. These data suggest that both VEGF and angiopoietins are involved in regulating tumor angiogenesis in human astrocytomas.
References
Arbiser, J.L., Moses, M.A., Fernandez, C.A., Ghiso, N., Cao, Y.,
Klauber, N., Frank, D., Brownlee, M., Flynn, E., Parangi, S., Byers, H.R., and
Folkman, J. (1997) Oncogenic H-ras stimulates tumor angiogenesis
by two distinct pathways. Proc. Natl. Acad. Sci.
U.S.A. 94,861
-866.
Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103,159 -165.[ISI][Medline]
Berse, B., Brown, L.F., Van de Water, L., Dvorak, H.F., and Senger, D.R. (1992) Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol. Biol. Cell 3, 211-220.[Abstract]
Davis, S., Aldrich, T.H., Jones, P.F., Acheson, A., Compton, D.L., Jain, V., Ryan, T.E., Bruno, J., Radziejewski, C., Maisonpierre, P.C., and Yancopoulos, G.D. (1996) Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 87,1161 -1169.[CrossRef][ISI][Medline]
Dumont, D.J., Gradwohl, G.J., Fong, G.H., Auerbach, R., and Breitman, M.L. (1993) The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene 8,1293 -1301.[ISI][Medline]
Dumont, D.J., Gradwohl, G., Fong, G.H., Puri, M.C., Gertsenstein,
M., Auerbach, A., and Breitman, M.L. (1994) Dominant-negative and
targeted null mutations in the endothelial receptor tyrosine kinase, tek,
reveal a critical role in vasculogenesis of the embryo. Genes
Dev. 8,1897
-1909.
Feldkamp, M.M., Lau, N., Rak, J., Kerbel, R.S., and Guha, A. (1999) Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. Int. J. Cancer 81,118 -124.[CrossRef][ISI][Medline]
Folkman, J. (1996) Tumor angiogenesis and tissue factor. Nat. Med. 2,167 -168.[CrossRef][ISI][Medline]
Goldman, C.K., Kim, J., Wong, W.L., King, V., Brock, T., and Gillespie, G.Y. (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell 4,121 -133.[Abstract]
Guha, A., Feldkamp, M.M., Lau, N., Boss, G., and Pawson, A. (1997) Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15,2755 -2765.[CrossRef][ISI][Medline]
Hanahan, D. (1997) Signaling vascular morphogenesis
and maintenance. Science
277, 48-50.
Hertz, L., Peng, L., and Lai, J.C. (1998) Functional studies in cultured astrocytes. Methods 16,293 -310.[CrossRef][Medline]
Kleihues, P., Soylemezoglu, F., Schauble, B., Scheithauer, B.W., and Burger, P.C. (1995) Histopathology, classification, and grading of gliomas. Glia 15,211 -221.[CrossRef][ISI][Medline]
Koblizek, T.I., Weiss, C., Yancopoulos, G.D., Deutsch, U., and Risau, W. (1998) Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8,529 -532.[CrossRef][ISI][Medline]
Kukk, E., Wartiovaara, U., Gunji, Y., Kaukonen, J., Buhring, H.J., Rappold, I., Matikainen, M.T., Vihko, P., Partanen, J., Palotie, A., Alitalo, K., and Alitalo, R. (1997) Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells. Br. J. Haematol. 98,195 -203.[CrossRef][Medline]
Lin, P., Buxton, J.A., Acheson, A., Radziejewski, C., Maisonpierre,
P.C., Yancopoulos, G.D., Channon, K.M., Hale, L.P., Dewhirst, M.W., George,
S.E., and Peters, K.G. (1998) Antiangiogenic gene therapy
targeting the endothelium-specific receptor tyrosine kinase Tie2.
Proc. Natl. Acad. Sci. U.S.A.
95,8829
-8834.
Maisonpierre, P.C., Suri, C., Jones, P.F., Bartunkova, S., Wiegand,
S.J., Radziejewski, C., Compton, D., McClain, J., Aldrich, T.H., Papadopoulos,
N., Daly, T.J., Davis, S., Sato, T.N., and Yancopoulos, G.D.
(1997) Angiopoietin-2, a natural antagonist for Tie2 that
disrupts in vivo angiogenesis. Science
277, 55-60.
Mandriota, S.J., and Pepper, M.S. (1998) Regulation of
angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by
cytokines and hypoxia. Circ. Res.
83,852
-859.
Mustonen, T., and Alitalo, K. (1995) Endothelial
receptor tyrosine kinases involved in angiogenesis. J. Cell
Biol. 129,895
-898.
Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z.
(1999) Vascular endothelial growth factor (VEGF) and its
receptors. FASEB J. 13,9
-22.
Nister, M., Claesson-Welsh, L., Eriksson, A., Heldin, C.H., and
Westermark, B. (1991) Differential expression of platelet-derived
growth factor receptors in human malignant glioma cell lines. J.
Biol. Chem. 266,16755
-16763.
Okada, F., Rak, J.W., Croix, B.S., Lieubeau, B., Kaya, M., Roncari,
L., Shirasawa, S., Sasazuki, T., and Kerbel, R.S. (1998) Impact
of oncogenes in tumor angiogenesis: Mutant K-ras up-regulation of vascular
endothelial growth factor/vascular permeability factor is necessary, but not
sufficient for tumorigenicity of human colorectal carcinoma cells.
Proc. Natl. Acad. Sci. U.S.A.
95,3609
-3614.
Peters, K.G., Coogan, A., Berry, D., Marks, J., Iglehart, J.D., Kontos, C.D., Rao, P., Sankar, S., and Trogan, E. (1998) Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis. Br. J. Cancer 77, 51-56.[ISI][Medline]
Plate, K.H., and Risau, W. (1995) Angiogenesis in malignant gliomas. Glia 15,339 -347.[CrossRef][ISI][Medline]
Plate, K.H., Breier, G., Weich, H.A., and Risau, W. (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359,845 -848.[CrossRef][Medline]
Plate, K.H., Breier, G., Millauer, B., Ullrich, A., and Risau, W.
(1993) Up-regulation of vascular endothelial growth factor and
its cognate receptors in a rat glioma model of tumor angiogenesis.
Cancer Res. 53,5822
-5827.
Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S.,
Sasazuki, T., and Kerbel, R.S. (1995) Mutant ras oncogenes
upregulate VEGF/VPF expression: implications for induction and inhibition of
tumor angiogenesis. Cancer Res.
55,4575
-4580.
Shweiki, D., Itin, A., Soffer, D., and Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359,843 -845.[CrossRef][Medline]
Stratmann, A., Risau, W., and Plate, K.H. (1998) Cell
type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role
in glioblastoma angiogenesis. Am. J. Pathol.
153,1459
-1466.
Suri, C., Jones, P.F., Patan, S., Bartunkova, S., Maisonpierre, P.C., Davis, S., Sato, T.N., and Yancopoulos, G.D. (1996). Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87,1171 -1180.[CrossRef][ISI][Medline]
Suri, C., McClain, J., Thurston, G., McDonald, D.M., Zhou, H.,
Oldmixon, E.H., Sato, T.N., and Yancopoulos, G.D. (1998)
Increased vascularization in mice overexpressing angiopoietin-1.
Science 282,468
-471.
Vikkula, M., Boon, L.M., Carraway, K.L., 3rd, Calvert, J.T., Diamonti, A.J., Goumnerov, B., Pasyk, K.A., Marchuk, D.A., Warman, M.L., Cantley, L.C., Mulliken, J.B., and Olsen, B.R. (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87,1181 -1190.[CrossRef][ISI][Medline]
Wong, A.L., Haroon, Z.A., Werner, S., Dewhirst, M.W., Greenberg,
C.S., and Peters, K.G. (1997) Tie2 expression and phosphorylation
in angiogenic and quiescent adult tissues. Circ. Res.
81,567
-574.
This article has been cited by other articles:
|
|
 |
|
  E. R. Smith, D. Zurakowski, A. Saad, R. M. Scott, and M. A. Moses Urinary Biomarkers Predict Brain Tumor Presence and Response to Therapy Clin. Cancer Res., April 15, 2008; 14(8): 2378 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Zhou, P. Guo, and J. M. Gallo Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide Clin. Cancer Res., March 1, 2008; 14(5): 1540 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S.N. Shim, I. A.W. Ho, and P. E.H. Wong Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis Mol. Cancer Res., July 1, 2007; 5(7): 655 - 665. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Niu and W. B. Carter Human Epidermal Growth Factor Receptor 2 Regulates Angiopoietin-2 Expression in Breast Cancer via AKT and Mitogen-Activated Protein Kinase Pathways Cancer Res., February 15, 2007; 67(4): 1487 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Fathers, C. M. Stone, K. Minhas, J. J.A. Marriott, J. D. Greenwood, D. J. Dumont, and B. L. Coomber Heterogeneity of Tie2 Expression in Tumor Microcirculation: Influence of Cancer Type, Implantation Site, and Response to Therapy Am. J. Pathol., December 1, 2005; 167(6): 1753 - 1762. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Shannon, N. Sabha, N. Lau, D. Kamnasaran, D. H. Gutmann, and A. Guha Pathological and Molecular Progression of Astrocytomas in a GFAP:12V-Ha-Ras Mouse Astrocytoma Model Am. J. Pathol., September 1, 2005; 167(3): 859 - 867. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Yang, O. Agapova, A. Parker, W. Shannon, P. Pecen, J. Duncan, M. Salvador-Silva, and M. R. Hernandez DNA microarray analysis of gene expression in human optic nerve head astrocytes in response to hydrostatic pressure Physiol Genomics, April 13, 2004; 17(2): 157 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Zadeh, B. Qian, A. Okhowat, N. Sabha, C. D. Kontos, and A. Guha Targeting the Tie2/Tek Receptor in Astrocytomas Am. J. Pathol., February 1, 2004; 164(2): 467 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Khatua, K. M. Peterson, K. M. Brown, C. Lawlor, M. R. Santi, B. LaFleur, D. Dressman, D. A. Stephan, and T. J. MacDonald Overexpression of the EGFR/FKBP12/HIF-2{alpha} Pathway Identified in Childhood Astrocytomas by Angiogenesis Gene Profiling Cancer Res., April 15, 2003; 63(8): 1865 - 1870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van den Bent, O.-L. Chinot, and J. G. Cairncross Recent developments in the molecular characterization and treatment of oligodendroglial tumors Neuro-oncol, April 1, 2003; 5(2): 128 - 138. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
